RxDoctor Payments Data

Ali Suleiman, MD

Nephrology · Beckley, WVNPI 1720167687

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Intuitive Surgical at 36.2% of the total. Reporting peaked in 2022 at $580 and has fallen 99.3% since, to $4 in 2025.

$1,342in general payments, 2019–2025

Across 28 payments — averaging $47.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$486
  • Fresenius USA Marketing, Inc.$161
  • Mallinckrodt Enterprises LLC$122
  • Vifor Pharma, Inc.$106
  • Akebia Therapeutics Inc$83
  • Novo Nordisk$79
  • plus $305 from 6 others

What the payments were for

  • Travel & lodging$48636%
  • Food & beverage$70953%
  • Education$14611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,342 in reported general payments places this provider in the 55th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$293,166
Medicare patients
322
Services billed
2,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide76$203,486
AuryxiaFerric Citrate20$33,860
Sevelamer Carbonate170$16,904
FarxigaDapagliflozin Propanediol11$8,372
LokelmaSodium Zirconium Cyclosilicate13$5,980
Calcium Acetate23$1,169
Losartan Potassium57$784
Lisinopril163$549
Hydralazine Hcl57$532
Labetalol Hcl24$500
Clonidine Hcl62$477
Doxazosin Mesylate42$467
Minoxidil12$445
Potassium Chloride39$420
Amlodipine Besylate114$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$161$203,48676 claims
Akebia Therapeutics IncAuryxia$83$33,86020 claims
AstraZenecaFarxiga, Lokelma$67$14,35324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 55 nephrology providers in West Virginia.

Other nephrology in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →